STOCK TITAN

CCXI - CCXI STOCK NEWS

Welcome to our dedicated page for CCXI news (Ticker: CCXI), a resource for investors and traders seeking the latest updates and insights on CCXI stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CCXI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CCXI's position in the market.

Rhea-AI Summary

ChemoCentryx (CCXI) has received EU approval for TAVNEOS (avacopan) to treat severe, active granulomatosis polyangiitis (GPA) and microscopic polyangiitis (MPA) in adults. This follows its FDA approval in October 2021. TAVNEOS, a first-in-class oral medication, is part of a partnership with Vifor Pharma, which will market the drug outside the U.S. ChemoCentryx will receive royalties on ex-U.S. sales. The drug addresses significant unmet medical needs in ANCA-associated vasculitis, with further development planned for C3 glomerulopathy and other diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) announced that CEO Thomas J. Schall, Ph.D. will present at two investor conferences. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 12 at 4:30 p.m. ET, while the H.C. Wainwright Virtual BioConnect Conference will have an on-demand presentation available starting January 10 at 7:00 a.m. ET. Both presentations can be accessed via the company's website, with replays available for two weeks after.

ChemoCentryx specializes in developing treatments for inflammatory and autoimmune diseases and cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization for TAVNEOS (avacopan) to treat severe, active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). This recommendation follows recent approvals in the U.S. and Japan. The European Commission's decision is expected in January 2022. Vifor Pharma holds exclusive rights for commercialization outside the U.S., with royalties expected in the teens to mid-twenties percent on net sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) announced that CEO Thomas J. Schall will participate in two investor conferences in November 2021. The first event is the Stifel 2021 Virtual Healthcare Conference, featuring a fireside chat on November 17 at 2:00 p.m. ET. The second is the Piper Sandler 33rd Annual Virtual Healthcare Conference, with an on-demand presentation available from November 22 at 10:00 a.m. ET. Live webcasts and replays will be accessible on the company's website for two weeks post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

ChemoCentryx announced FDA approval of TAVNEOS (avacopan) for treating severe ANCA-associated vasculitis, marking its market launch in the U.S. This first-of-its-kind oral medication targets granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), providing new hope for patients. The company reported a third-quarter revenue of $17.7 million, up from $5.1 million in 2020, driven by a $20 million milestone payment. ChemoCentryx has significant cash reserves of $372 million, supporting ongoing clinical developments. Upcoming regulatory opinions and trials are anticipated for further pipeline expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

ChemoCentryx (Nasdaq: CCXI) recently announced accepted abstracts for presentation at the ASN Kidney Week and ACR Convergence 2021 from November 2-9, focusing on its treatment, TAVNEOS (avacopan), a selective C5a receptor inhibitor. Key findings include the potential of avacopan to enhance kidney function in patients with ANCA-associated vasculitis and improve health-related quality of life compared to standard treatments. The presentations could influence future clinical practices and enhance avacopan's profile in treating autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) will release its third quarter 2021 financial results after market close on November 9, 2021. A conference call with management will follow at 5:00 p.m. ET on the same day to discuss the results and address questions. Investors can access the live and archived audio webcast on the company’s website for 14 days post-call. ChemoCentryx is known for developing medications for inflammatory and autoimmune diseases, notably TAVNEOS, the first approved oral inhibitor for treating severe active ANCA-associated vasculitis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

ChemoCentryx announces the appointment of Rita I. Jain, M.D., as Executive Vice President and Chief Medical Officer. Dr. Jain brings over 20 years of drug development experience and will oversee clinical development and regulatory affairs. She is a board-certified rheumatologist and has a notable background, including leadership roles at Immunovant and Akebia. This strategic addition enhances ChemoCentryx's leadership team as the company progresses towards the launch of its first product, TAVNEOS, which is approved for treating ANCA-associated vasculitis and in late-stage development for other conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

ChemoCentryx announced FDA approval for TAVNEOS (avacopan), the first orally-administered inhibitor of the complement 5a receptor, for adult patients with severe ANCA-associated vasculitis. This approval supports treatment for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) as an adjunctive therapy alongside standard treatments. The pivotal Phase III ADVOCATE trial demonstrated efficacy in achieving disease remission, marking a significant milestone in treatment options for this life-threatening condition. TAVNEOS Connect, a patient support program, will assist patients starting on TAVNEOS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

ChemoCentryx has received approval in Japan for TAVNEOS™ (avacopan) from the Ministry of Health, Labor, and Welfare. This first-in-class medication is designed for treating microscopic polyangiitis and granulomatosis with polyangiitis, forms of ANCA-associated vasculitis. The company formed a partnership with Kissei Pharmaceutical, granting them exclusive rights for commercialization in Japan. The FDA is expected to make a decision on TAVNEOS on October 7, 2021, with further regulatory evaluations in Europe anticipated by the end of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the market cap of CCXI (CCXI)?

The market cap of CCXI (CCXI) is approximately 3.7B.
CCXI

Nasdaq:CCXI

CCXI Rankings

CCXI Stock Data

3.74B
62.84M
12.01%
84.39%
10.58%
Biotechnology
Healthcare
Link
United States
San Carlos